Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811902 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT00811902 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 405 participants.
The verdict
NCT00811902, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: * To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject and clinical assessment of change by the Study Investigator * To assess the safety and tolerance of nerispirdine * To evaluate the pharmacokinetics (PK) parameters of nerispirdine
Interventions
- DRUG placebo
- DRUG Nerispirdine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811902
The ClinicalTrials.gov registry entry for NCT00811902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00811902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811902 about?
NCT00811902 is a clinical study titled "Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis". The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: * To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject a...
What is the current status of trial NCT00811902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2008-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00811902?
The interventions under investigation include: placebo (DRUG), Nerispirdine (DRUG).
Who is sponsoring clinical trial NCT00811902?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.